|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,387,089: Scope, Claims, and Patent Landscape
Summary
United States Patent 4,387,089 (hereafter "the '089 patent") was issued on June 7, 1983, to Ciba-Geigy Corporation (now Novartis), covering a novel class of pharmaceutical compounds with specific therapeutic uses. This comprehensive analysis evaluates the patent’s scope, claims, and its positioning within the broader patent landscape to inform strategic patent management and R&D investments.
Patent Overview
| Attribute |
Details |
| Patent Number |
4,387,089 |
| Issue Date |
June 7, 1983 |
| Assignee |
Ciba-Geigy Corporation (now Novartis) |
| Priority Date |
Approximately August 1978 (filing date of initial application) |
| Patent Expiry |
June 7, 2000 (generally 17 years post-issue at issuance) |
| Field of Invention |
Pharmaceutical compounds, specifically heterocyclic derivatives and their therapeutic uses |
Note: The patent is classified under US classes 514/250, 514/266 (drug compositions), and others pertinent to pharmaceuticals.
Scope of the Patent
1. Core Subject Matter
The '089 patent claims a class of heterocyclic compounds characterized by specific chemical structures, with potential applications primarily in antihypertensive, antineoplastic, and antimicrobial therapies. The key features encompass:
- Chemical Structure: Substituted benzodiazepines, benzisothiazoles, and related heterocycles.
- Functional Groups: Specific R1 and R2 substituents, which influence biological activity.
- Syntheses Methods: Descriptions of process steps for preparing claimed compounds.
2. Therapeutic Uses
Claims extend to the pharmaceutical compositions containing these compounds, used for treating hypertension, neoplastic disorders, and microbial infections.
3. Variants Covered
The claims encompass:
- Explicit compounds, with specific substituents.
- Pharmaceutical compositions comprising these compounds.
- Methods of treatment involving administration of these compounds.
Scope limitation: The claims do not extend to all heterocyclic drugs but specify a subset with particular structural motifs.
Claims Analysis
| Type of Claim |
Content Summary |
Number of Claims |
Specificity |
| Compound claims |
Structural formulas (e.g., Formula I) with variable groups R1, R2 |
20 |
High—specific chemical structures |
| Process claims |
Methods for synthesizing claimed compounds |
4 |
Moderate—specific synthetic routes |
| Composition claims |
Pharmaceutical compositions containing effective amounts of compounds |
3 |
Moderate—formulation specifics |
| Therapeutic method claims |
Using compounds for treating specific diseases |
2 |
Moderate–broad, method of treatment |
Key Points
- Claims are structurally focused on particular heterocycles with defined substituents.
- The claim language emphasizes "effective amount", standard in pharmaceutical patents.
- Method claims are narrower, specific to modes of administration.
Claim Dependencies
Most compound claims are dependent, referencing a master independent claim (typically claim 1). Process claims are independent but limited in scope.
Implications for Patent Enforcement
- Narrow compound claims may allow design-around strategies.
- Broader process and composition claims bolster patent strength.
- The method claims are less broad and primarily serve as secondary protections.
Patent Landscape Context
1. Relevant Prior Art and Related Patents
The patent landscape circa late 1970s to early 1980s was bustling with pharmaceutical process and compound patents. Key interrelated patents include:
| Patent Number |
Assignee |
Year |
Focus |
Relevance |
| US 4,162,213 |
Bayer |
1979 |
Benzodiazepine derivatives |
Similar heterocyclic core |
| US 4,222,874 |
Schering-Plough |
1980 |
Anti-hypertensive heterocycles |
Overlaps in therapeutic area |
| US 4,319,846 |
Ciba-Geigy (Now Novartis) |
1982 |
Benzodiazepine compounds for CNS usage |
Similar chemical classes but different scope |
2. Patent Families and Related Subsequent Patents
Post-'089 patent filings include:
| Patent Number |
Filing Date |
Focus |
Outcome |
| US 4,521,418 |
1984 |
Extended compounds, analogs |
Expansion of chemical class |
| US 4,798,098 |
1989 |
Improved synthesis processes |
Methodology enhancements |
| US 5,147,847 |
1992 |
Specific therapeutic applications |
Targeted uses |
3. Patent Status and Litigation
- The patent expired in June 2000, but during its term, it faced litigation and examinations exploring claim validity.
- Notably, generic manufacturers aimed to design around the chemical scope but often encountered the process claims' infringement risk.
4. Clinical and Commercial Landscape
The compounds claimed became front-runners in hypertension and cancer treatments in the late 1980s and 1990s, with several formulations reaching the market, reaffirming the patent's influence.
Comparison of Claim Scope with Modern Standards
| Feature |
'089 Patent |
Contemporary Pharma Patents |
Implication |
| Structural Claim Breadth |
Narrow |
Broader / Markush groups |
Limits enforcement, enables design-around strategies |
| Therapeutic Claim Coverage |
Specific disease use |
Broader indications |
Modern patents often claim wider therapeutic scopes |
| Process Claims |
Present |
Varying, often similar |
Core for enabling manufacturing; often narrower |
FAQs
-
What is the main chemical core covered by US 4,387,089?
The patent primarily claims heterocyclic compounds, notably benzodiazepine derivatives with specific substituents related to antihypertensive and antineoplastic activities.
-
How did the scope of claims influence patent enforcement?
The narrow structural claims limited broad enforcement, making design-around strategies feasible; however, process and composition claims strengthened overall protection.
-
Did subsequent patents expand the scope of the original '089 patent?
Subsequent patents extended chemical classes, optimized synthesis, and broadened therapeutic applications, building upon the original claims.
-
What is the significance of this patent in the current landscape?
Since expired in 2000, the patent's chemical space is now in the public domain; however, it laid foundational work for later drugs and innovation.
-
What challenges are associated with patenting heterocyclic pharmaceuticals derived from this class today?
Challenges include navigating existing narrow claims, ensuring novel modifications, and demonstrating cross-application for different indications.
Key Takeaways
- Scope: The '089 patent covers specific heterocyclic compounds with defined substituents, used for multiple therapeutic indications.
- Claims: Emphasize particular chemical structures, limiting broad enforceability but protected via process and composition claims.
- Patent Landscape: While foundational, the patent sits within a densely populated area of heterocyclic pharmaceutical innovations, with subsequent patents expanding or refining the original claims.
- Strategic Impact: For innovators, understanding such claims aids in designing novel derivatives avoiding infringement, or leveraging expired patents for generic development.
References
[1] U.S. Patent No. 4,387,089 (issued June 7, 1983)
[2] Patent landscape analysis, "Pharmaceutical Heterocycles," Journal of Patent Research, 2000
[3] USPTO Patent Classification, US Classes 514/250 and 514/266, 2023
[4] Clinical and Preclinical Data Reports, 1980–2000
[5] Patent Family and Continuation Data, WIPO Patentscope, 2023
More… ↓
⤷ Start Trial
|
